Here Are Some Essential Facts About Viking Therapeutics (VKTX)

Shares of Small-cap health care company Viking Therapeutics moved 3.8 this evening, and are now trading at $20.38 per share. On the other hand, the average analyst target price for the stock is $None.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Viking Therapeutics investors should be aware of the below:

Viking Therapeutics has moved 655.0% over the last year.

The company has a price to earnings growth (PEG) ratio of -0.48. A number between 0 and 1 could mean that the market is undervaluing Viking Therapeutics's estimated growth potential

Its Price to Book (P/B) ratio is 11.0

Viking Therapeutics currently returns an annual dividend yield of None%.


The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.